Leapfrog Bio announced on March 24, 2026, the appointment of Alan Ashworth, Ph.D., FRS, to chair the company's Scientific Advisory Board12
Dr. Ashworth is a world-renowned cancer research expert who played a key role in identifying the BRCA2 gene and establishing its role in DNA repair and homologous recombination12
His lab discovered the synthetic lethality relationship between BRCA1/2 and PARP inhibitors, which guided the development of olaparib, the first approved genetically targeted PARP inhibitor12
Leapfrog Bio is a clinical-stage precision oncology company focused on discovering novel targeted therapies for cancers caused by loss-of-function mutations12
The company's pipeline includes LFB190, a Phase 2-ready BET inhibitor for solid tumors with EP300 loss-of-function mutations, and LFB083, which targets cancers driven by PIK3CA mutations12
Dr. Ashworth currently serves as President of the Helen Diller Family Comprehensive Cancer Center at UCSF and Senior Vice President for Cancer Clinical Services at UCSF Health12
Dr. Ashworth is also a co-founder of Tango Therapeutics, Azkarra, and Tiller, and previously served as CEO of the Institute of Cancer Research in London12
Sources:
1. https://www.biospace.com/press-releases/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board
2. https://www.globenewswire.com/news-release/2026/03/24/3261170/0/en/Leapfrog-Bio-Appoints-Alan-Ashworth-Ph-D-FRS-to-Chair-Company-s-Scientific-Advisory-Board.html